MPN present many significant clinical challenges for clinicians, and though considerable progress has been made in particular with the JAK1 and JAK2 inhibitor ruxolitinib, more effective alternative therapeutic approaches are needed. Here, JAK2 is linked to myeloproliferative disorder.